stoxline Quote Chart Rank Option Currency Glossary
  
Hoth Therapeutics, Inc. (HOTH)
1.295  0 (0%)    02-23 15:59
Open: 1.27
High: 1.33
Volume: 4,219
  
Pre. Close: 1.295
Low: 1.2683
Market Cap: 6(M)
Technical analysis
2024-02-23 4:37:13 PM
Short term     
Mid term     
Targets 6-month :  1.59 1-year :  1.7
Resists First :  1.36 Second :  1.45
Pivot price 1.36
Supports First :  1.22 Second :  1.01
MAs MA(5) :  1.33 MA(20) :  1.36
MA(100) :  1.29 MA(250) :  1.88
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  27.5 D(3) :  38
RSI RSI(14): 44.3
52-week High :  4.3 Low :  0.99
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ HOTH ] has closed above bottom band by 10.6%. Bollinger Bands are 44.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.33 - 1.34 1.34 - 1.35
Low: 1.25 - 1.26 1.26 - 1.27
Close: 1.28 - 1.3 1.3 - 1.31
Company Description

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Headline News

Tue, 13 Feb 2024
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024 - Yahoo Canada Finance

Tue, 06 Feb 2024
Is Hoth Therapeutics Inc (HOTH) a Stock to Watch After Losing -1.47% This Week? - InvestorsObserver

Mon, 05 Feb 2024
Hoth Therapeutics stock gets Buy rating as it meets 'unmet medical needs' By Investing.com - Investing.com

Thu, 18 Jan 2024
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients - PR Newswire

Wed, 27 Dec 2023
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 ... - PR Newswire

Tue, 05 Dec 2023
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer Fighting HT-KIT for IND ... - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 4 (M)
Shares Float 4 (M)
Held by Insiders 0.9 (%)
Held by Institutions 2.1 (%)
Shares Short 113 (K)
Shares Short P.Month 301 (K)
Stock Financials
EPS -4.72
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.42
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -53.6 %
Return on Equity (ttm) -100.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -8 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio -0.28
PEG Ratio 0
Price to Book value 0.53
Price to Sales 0
Price to Cash Flow -0.72
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android